4Indexed trials
drug · Product Intelligence
Metformin
Pipeline Intelligence
Metformin: 4 indexed trials, 4 sponsors; 7 linked Orange Book patents and 12 FDA-linked events where matched.
4Sponsors
7Orange Book patent links
12FDA-linked events
Development evidence
NCT00806234Johns Hopkins University · schizophreniaPHASE4
NCT03862950University of Alberta · intellectual_disabilityPHASE2
NCT04930471Insel Gruppe AG, University Hospital Bern · autismUNKNOWN
NCT05722951Tanta University · epilepsyPHASE3
FDA / patent evidence
8080580SEGLUROMET · app 2098062031-12-19
9439902SEGLUROMET · app 2098062030-10-21
9308204SEGLUROMET · app 2098062030-10-21
8900638KAZANO · app 2034142029-05-24
9320714ACTOPLUS MET · app 0218422029-02-03
7807689KAZANO · app 2034142028-06-27
9101660ACTOPLUS MET · app 0218422027-01-22
Regulatory context
FDA_EXCLUSIVITYKAZANO · M-3002026-07-27
FDA_APPROVALZITUVIMET · 2023-11-03
FDA_APPROVALMETFORMIN HYDROCHLORIDE · 2021-03-09
FDA_APPROVALSEGLUROMET · 2017-12-19
FDA_APPROVALKAZANO · 2013-01-25
FDA_APPROVALMETFORMIN HYDROCHLORIDE · 2012-07-20
FDA_APPROVALMETFORMIN HYDROCHLORIDE · 2010-11-01
FDA_APPROVALMETFORMIN HYDROCHLORIDE · 2007-01-24
FDA_APPROVALMETFORMIN HYDROCHLORIDE · 2006-07-28
FDA_APPROVALACTOPLUS MET · 2005-08-29
FDA_APPROVALGLYBURIDE AND METFORMIN HYDROCHLORIDE · 2005-01-27
FDA_APPROVALMETFORMIN HYDROCHLORIDE · 2004-12-14
FDA Orange Book coverage is U.S.-specific and is not a substitute for worldwide patent or regulatory review.